Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy SCYNEXIS stock in Canada | $9.58

Own SCYNEXIS shares in just a few minutes.

-$0.10 (-1.43%)

SCYNEXIS is a drug manufacturers-specialty & generic business based in the US. SCYNEXIS stocks (SCYX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.53 – an increase of 7.04% over the previous week. SCYNEXIS employs 38 staff and has a trailing 12-month revenue of around $12.1 million.

How to buy SCYNEXIS stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: SCYX in this case.
  5. Research SCYNEXIS stocks. The platform should provide the latest information available.
  6. Buy your SCYNEXIS stocks. It's that simple.

How has Coronavirus impacted SCYNEXIS's stock price?

Since the stock market crash in March caused by coronavirus, SCYNEXIS's stock price has had significant positive movement.

Its last market close was $9.58, which is 88.52% up on its pre-crash value of $1.1 and 1,816.00% up on the lowest point reached during the March crash when the stocks fell as low as $0.5.

If you had bought $1,000 worth of SCYNEXIS stocks at the start of February 2020, those stocks would have been worth $800.66 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $11,279.88.

SCYNEXIS stock price

Use our graph to track the performance of SCYX stocks over time.

SCYNEXIS stocks at a glance

Information last updated 2021-07-28.
Latest market close$9.58
52-week range$4.2009 - $10.25
50-day moving average $7.4711
200-day moving average $7.949
Wall St. target price$25.5
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.587

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy SCYNEXIS stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

SCYNEXIS price performance over time

Historical closes compared with the last close of $9.58

1 month (2021-07-02) 21.42%
3 months (2021-04-30) 26.72%

SCYNEXIS financials

Revenue TTM USD$12.1 million
Gross profit TTM USD$121,000
Return on assets TTM -35.55%
Return on equity TTM -326.5%
Profit margin 0%
Book value $1.257
Market capitalisation USD$151 million

TTM: trailing 12 months

How to short and sell SCYNEXIS stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "SCYX.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 3.7 million SCYNEXIS stocks held short by investors – that's known as SCYNEXIS's "short interest". This figure is 1.7% down from 3.8 million last month.

There are a few different ways that this level of interest in shorting SCYNEXIS stocks can be evaluated.

SCYNEXIS's "short interest ratio" (SIR)

SCYNEXIS's "short interest ratio" (SIR) is the quantity of SCYNEXIS stocks currently shorted divided by the average quantity of SCYNEXIS stocks traded daily (recently around 391773.87198321). SCYNEXIS's SIR currently stands at 9.53. In other words for every 100,000 SCYNEXIS stocks traded daily on the market, roughly 9530 stocks are currently held short.

However SCYNEXIS's short interest can also be evaluated against the total number of SCYNEXIS stocks, or, against the total number of tradable SCYNEXIS stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case SCYNEXIS's short interest could be expressed as 0.18% of the outstanding stocks (for every 100,000 SCYNEXIS stocks in existence, roughly 180 stocks are currently held short) or 0.2273% of the tradable stocks (for every 100,000 tradable SCYNEXIS stocks, roughly 227 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against SCYNEXIS.

Find out more about how you can short SCYNEXIS stock.

SCYNEXIS stock dividends

We're not expecting SCYNEXIS to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have SCYNEXIS stocks ever split?

SCYNEXIS stocks were split on a 1:10 basis on 17 July 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your SCYNEXIS stocks – just the quantity. However, indirectly, the new 900% higher stock price could have impacted the market appetite for SCYNEXIS stocks which in turn could have impacted SCYNEXIS's stock price.

SCYNEXIS stock price volatility

Over the last 12 months, SCYNEXIS's stocks have ranged in value from as little as $4.2009 up to $10.25. A popular way to gauge a stock's volatility is its "beta".

SCYX.US volatility(beta: 2.1)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while SCYNEXIS's is 2.0963. This would suggest that SCYNEXIS's stocks are significantly more volatile than the average for this exchange and represent a higher risk.

SCYNEXIS overview

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site